The Link Between Air Pollution and Autism

The California Institute for Regenerative Medicine (CIRM) is supporting innovative research into neuro diseases, including a project examining how air pollution may contribute to autism. Through the Research using Multidisciplinary, Innovative approaches in Neuro Diseases (ReMIND) program, Stuart Lipton, MD, PhD, and co-investigators Tomo Nakamura, PhD, John Yates, PhD, Marisa Roberto, PhD, and Nik Schork, … Continue reading The Link Between Air Pollution and Autism

Using Genetic Sequencing and AI to Identify and Treat Schizophrenia

Top left to right: Tomasz Nowakowski, PhD, and Nevan Krogan, PhD Bottom left to right: Aparna Bhaduri, PhD; Matt State, PhD; Alice Ting, PhD; Trey Ideker, PhD; Willow Coyote-Maestas, PhD A UC San Francisco research team funded by the California Institute for Regenerative Medicine (CIRM) is using AI models to explore potential stem cell and … Continue reading Using Genetic Sequencing and AI to Identify and Treat Schizophrenia

Upcoming Funding Opportunity: ReMIND-L Awards

The California Institute for Regenerative Medicine (CIRM) is pleased to announceย ReMIND-L, the first funding opportunity under CIRMโ€™s ReMIND Program โ€“ a new discovery stage initiative supporting foundational research in the study of neuropsychiatric diseases. ย ย Applications areย due March 5, 2024 by 2:00 p.m. PST. Applications will be available mid-December 2023 but no later than two months … Continue reading Upcoming Funding Opportunity: ReMIND-L Awards

CIRM approves new plan to invest $110 million into basic research in neuropsychiatric diseases

The California Institute for Regenerative Medicine, the worldโ€™s largest institute dedicated to regenerative medicine, announced its approval of a new program called ReMIND at the September Independent Citizens Oversight Committee (ICOC) meeting that will eventually award up to $110 million to advance basic research in neuropsychiatric diseasesโ€”one of the largest investments of its kind in … Continue reading CIRM approves new plan to invest $110 million into basic research in neuropsychiatric diseases